C

Clinical Science Institute | Santa Monica, CA

Research site
(Unclaimed)
Location
2001 Santa Monica Boulevard, Suite 1160W and 1185W, Santa Monica, California, United States of America
Site insights

Top conditions

Psoriasis (41 trials)

Atopic Dermatitis (30 trials)

Dermatitis (30 trials)

Eczema (27 trials)

Acne Vulgaris (4 trials)

Top treatments

PF-04965842
PF-06700841
Dupilumab
Apremilast
Rocatinlimab
Guselkumab
Ixekizumab
Lebrikizumab
LY3009104
CP-690,550

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

23 of 87
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLVE-AD)

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-...

Enrolling
Moderate to Severe Atopic Dermatitis
Drug: Placebo
Drug: Rezpegaldesleukin

The co-primary objectives of the study are to:Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Validated Invest...

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atop...

Enrolling
Atopic Dermatitis
Drug: Lebrikizumab
Locations recently updated

The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 1...

Enrolling
Plaque Psoriasis
Drug: Apremilast

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Enrolling
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Enrolling
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.

Enrolling
Plaque Psoriasis
Drug: LY3972406
Drug: Placebo

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

The primary objectives of the study are to evaluate the efficacy of BIIB059 (litifilimab) compared with placebo in reducing skin disease activity mea...

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: BIIB059 (litifilimab)
Drug: Placebo

The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and ge...

Enrolling
Palmoplantar Psoriasis
Genital Psoriasis
Drug: Deucravacitinib
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subje...

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: Rocatinlimab

This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety...

Active, not recruiting
Plaque Psoriasis
Drug: DC-806
Other: Placebo

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of...

Enrolling
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

The study is designed to investigate efficacy and safety of KBL697 in patients with Moderate Plaque Type Psoriasis. KBL697 has been developed as a po...

Active, not recruiting
Psoriatic Plaque
Drug: KBL697

This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody re...

Enrolling
Dermatitis Atopic
Drug: Placebo
Biological: PPS vaccine

The purpose of this study is to learn about the safety and effects of the study medicine called etrasimod for the possible treatment of atopic dermat...

Active, not recruiting
Atopic Dermatitis
Eczema, Atopic
Drug: etrasimod
Drug: Placebo

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have bee...

Active, not recruiting
Psoriasis
Drug: BMS-986165

A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with m...

Enrolling
Discoid Lupus Erythematosus
Drug: Daxdilimab
Drug: Placebo/Daxdilimab

The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-...

Active, not recruiting
Scalp Psoriasis
Plaque Psoriasis
Drug: Guselkumab
Drug: Placebo

Trial sponsors

Pfizer logo

Pfizer (15 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems